Summary by Moomoo AI
TransCode Therapeutics, Inc., a clinical-stage oncology company, announced its financial results for the fourth quarter and full year ended December 31, 2023, on April 3, 2024. The company, which specializes in RNA therapeutics for cancer treatment, reported progress in its clinical trials and strategic collaborations. TransCode advanced its lead therapeutic candidate, TTX-MC138, into clinical trials as a first-in-class drug candidate targeting metastatic cancer. Despite a challenging financial market, the company raised over $25 million in equity financings. TransCode also signed agreements with Debiopharm and Akribion Genomics to develop cancer treatments and a CRISPR-derived technology platform, respectively. The company appointed Tom Fitzgerald as interim CEO and CFO, and Daniel Vlock, M.D., as Chief Medical Officer. TransCode regained compliance with Nasdaq's...Show More